Key reports from the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV 2007

Antiviral Therapy

Volumn 12, Issue 6, 2007, Pages 987-998

  Nestorowicz, Ann ^a   Cameron, Stephen ^b  

^a International Medical Press Ltd   (Australia)

^b International Medical Press Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; GROWTH HORMONE RELEASING FACTOR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PIOGLITAZONE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TH 9507; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

BONE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER DISEASE; LIVER TOXICITY; LONG TERM CARE; METABOLIC DISORDER; MONOTHERAPY; OSTEOPENIA; OSTEOPOROSIS; PATIENT CARE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; DRUG HYPERSENSITIVITY; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE;

EID: 34848855837     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (89)

1. Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther 2007; 12:149-162.
2. Koutkia P, Grinspoon S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annu Rev Med 2004; 55:303-317.
3. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184.
4. van Vonderen MGA, Blumer RME, Hassink E, et al. Zidovudine/lamivudine persistently contributes to peripheral insulin resistance by a body composition-independent mechanism demonstrated by repeated clamp studies during 2 years of first-line ART with zidovudine/lamivudine/lopinavir/ ritonavir. Antivir Ther 2007; 12:L13.
5. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; 292:E1666-E1673.
6. Lee GA, Schwarz JM, Patzek S, et al. The acute effects of HIV protease inhibitors on glucose production in healthy HIV-negative men. Antivir Ther 2007; 12:L46.
7. Carr A, Zajdenverg R, Workman C, et al. Effects of tipranavir/r (500/200 or 500/100 mg BID) in comparison with lopinavir/r (400/100 mg BID) on changes in body composition and metabolic parameters in ARV-naive patients over 48 weeks. Antivir Ther 2007; 12:L8.
8. Boothby M, Tomlinson JW, McGee KC, et al. The effect of antiretroviral therapy on genes involved with glucose and lipid metabolism. Antivir Ther 2007; 12:L12.
9. Sukhija R, Kakar P, Mehta V, et al. Enhanced 11β- hydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension. Am J Cardiol 2006; 98:544-548.
10. Sutinen J, Kannisto K, Korsheninnikova E, et al. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of Cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004; 47:1668-1671.
11. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031.
12. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are interrelated and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004; 9:555-564.
13. Villarroya F, Domingo P, Giralt M. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int J Obes (Lond) 2007; in press.
14. Avettand-Fenoel V, Kim M, Antuna B, et al. Macrophage recruitment in adipose tissue from HIV-infected patients under ART: concomitant presence of classically activated pro-inflammatory M1 and alternatively activated M2 macrophages. Antivir Ther 2007; 12:L12.
15. Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin action in adipocytes by altering expression of signalling and glucose transport proteins. Am J Physiol Endocrinol Metab 2007; 292:E166-E174.
16. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117:175-184.
17. Addy CL, Gavrila A, Tsiodras S, et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003; 88:627-636.
18. Lee GA, Mafong DD, Noor MA, et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004; 36:645-647.
19. Kosmiski L, Kotler DP, Lewis CE, et al. Relationship of fat distribution with adipokines in HIV-infection: the FRAM study. Antivir Ther 2007; 12:L16.
20. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-131.
21. Tong Q, Sankale JL, Hadigan CM, et al. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 2003; 88:1559-1564.
22. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
23. Mondy K, Tebas P. Cardiovascular risks of antiretroviral therapies. Annu Rev Med 2007; 58:141-155.
24. Currier JS, Kendall MA, Henry WK, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007; 21:1137-1145.
25. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
26. Kingsley LA, Cuervo J, Munoz A, et al. Subclinical coronary atherosclerosis, HIV-infection and antiretroviral therapy; results from the multicentre AIDS cohort study. Antivir Ther 2007; 12:L11.
27. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006; 114:1761-1791.
28. Budoff MJ, Gopal A, Gopalakrishnan D. Cardiac computed tomography: diagnostic utility and integration in clinical practice. Clin Cardiol 2006; 29:I4-14.
29. Young J, Glass T, Weber R, et al. The rate at which therapy-naive patients develop metabolic syndrome when treated and its associations with different components of antiretroviral therapy: the Swiss Cohort Study. Antivir Ther 2007; 12:L10.
30. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366:1059-1062.
31. Andrade AC, Cotter BR. Endothelial function and cardiovascular diseases in HIV infected patient. Braz J Infect Dis 2006; 10:139-145.
32. Cotter BR. Endothelial dysfunction in HIV infection. Curr HIV/AIDS Rep 2006; 3:126-131.
33. Wang X, Chai H, Yao Q, et al. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007; 44:493-499.
34. Dubé M, Shen C, Greenwald ML, et al. Effects of 4 weeks of atazanavir, lopinavir/ritonavir or placebo on endothelial function and insulin sensitivity in healthy men. Antivir Ther 2007; 12:L14.
35. Shankar SS, Dubé MP, Gorski JC, et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005; 150:933.
36. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-F18.
37. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16:F1-F8.
38. Torriani FJ, Komarow L, Cotter BR, et al. Control of HIV viral replication is associated with rapid improvement in endothelial function sustained over 24 weeks: A5152s, a substudy of A5142. Antivir Ther 2007; 12:L15.
39. Dubé M, Shen C, Waltz JS, et al. Relationship of body composition, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. Antivir Ther 2007; 12:L15.
40. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15:2407-2414.
41. Negredo E, Ribalta J, Ferre R, et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 2004; 18:819-821.
42. Sankatsing RR, Franssen R, Hassink E, et al. Nevirapine increases high density lipoprotein-cholesterol by stimulation of apolipoprotein A1 synthesis. Antivir Ther 2007; 12:L5.
43. Flint OP, Bellamine A, Noor MA, et al. Effects of efavirenz on lipid metabolism in APOE*3*Leiden hCETP double-transgenic mice: evidence for antagonism of LXR pathway. Antivir Ther 2007; 12:L5.
44. Flint OP, Bellamine A, Noor MA, et al. Molecular mechanisms for efavirenz effects on lipid metabolism. Antivir Ther 2007; 12:L6.
45. Mehta U, Durrheim DN, Cohen K, et al. Design and outcomes of an antiretroviral pharmacovigilance programme in South Africa. Antivir Ther 2007; 12:L7.
46. Aldrovandi GM, Lindsey JC, Jacobsen D, et al. Dyslipidemia in vertically infected children and youth on protease-inhibitor (PI)-containing antiretroviral therapy (ART): preliminary results of PACTG 1045. Antivir Ther 2007; 12:L6.
47. Gibert CL, Shlay JC, Sharma S, et al. Racial differences in long-term changes in metabolic parameters in antiretroviral-naive persons initiating HAART. Antivir Ther 2007; 12:L19.
48. Gibert CL, Shlay JC, Sharma S, et al. Racial differences in long-term changes in body composition in antiretroviral-naive persons initiating HAART. Antivir Ther 2007; 12:L19.
49. Karter AJ, Ferrara A, Liu JY, et al. Ethnic disparities in diabetic complications in an insured population. JAMA 2002; 287:2519-2527.
50. Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care 2001; 24:454-459.
51. Pugh JA, Stern MP, Haffner SM, et al. Excess incidence of treatment of end-stage renal disease in Mexican Americans. Am J Epidemiol 1988; 127:135-144.
52. Burger D, Boyd M, Duncombe C, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003; 51:1231-1238.
53. Boyd M, Mootsikapun P, Burger D, et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther 2005; 10:301-307.
54. Ananworanich J, Hill A, Siangphoe U, et al. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir Ther 2005; 10:761-767.
55. van der Lugt J, Ruxrungtham K, Autar S, et al. Metabolic changes in a Thai treatment-naive population starting double-boosted protease inhibitor therapy. Antivir Ther 2007; 12:L7.
56. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174.
57. Bongiovanni M, Fausto A, Cicconi P, et al. Non-nucleoside-reverse- transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects. J Antimicrob Chemother 2006; 58:485-486.
58. Brown TT, McComsey GA. Osteopenia and osteoporosis in patients with HIV: a review of current concepts. Curr Infect Dis Rep 2006; 8:162-170.
59. Bonnet E, Mabile L, Ruidavets JB, et al. Important changes in bone metabolism soon after commencing HAART. Antivir Ther 2007; 12:L17.
60. Briot K, Kolta S, Flandre P, et al. One-year bone mineral density changes in antiretroviral-naive HIV-infected patients treated by a triple versus a single-agent regimen, with lopinavir/ritonavir in the Monark trial. Antivir Ther 2007; 12:L62.
61. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559-1585.
62. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145-1152.
63. Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39:1199-1206.
64. Gupta SK, Mamlin BW, Johnson CS, et al. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 2004; 61:1-6.
65. Kimmel PL. HIV-associated nephropathy: virological issues related to renal sclerosis. Nephrol Dial Transplant 2003; 18 Suppl 6:vi59-vi63.
66. Gupta SK, Komarow L, Gulick RM, et al. Proteinuria, creatinine clearance and immune activation in HIV-infected subjects: a secondary analysis of treatment-naive studies ACTG 384, A5095 and A5001. Antivir Ther 2007; 12:L17.
67. Jones R, Dunning J, Nelson M. HIV and hepatitis C coinfection. Int J Clin Pract 2005; 59:1082-1087.
68. Rockstroh J. HIV/hepatitis co-infection. J HIV Ther 2007; 12:1.
69. Rockstroh JK. Management of hepatitis C/HIV coinfection. Curr Opin Infect Dis 2006; 19:8-13.
70. Leen CL. Hepatitis C and HIV co-infection. Int J STD AIDS 2004; 15:289-294.
71. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
72. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
73. Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol 2006; 44:S28-S34.
74. Petrovic LM. HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article. Liver Int 2007; 27:598-606.
75. Barreiro P, Blanco F, de Mendoza C, et al. Metabolic syndrome and progression of liver fibrosis in HIV/HCV-coinfected patients on HAART. Antivir Ther 2007; 12:L64.
76. Wit F, Kesserling A, Gras L, et al. Incidence of hypersensitivity reactions associated with nevirapine-containing HAART in patients with prior treatment experience may differ from that in treatment-naive patients: the ATHENA cohort study. Antivir Ther 2007; 12:L4.
77. Tomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs 2006; 7:936-945.
78. Falutz J, Allas S, Mamputu J-C, et al. Further data on the effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, on body composition and metabolic parameters in HIV-infected patients with abdominal fat accumulation. Antivir Ther 2007; 12:L9.
79. Turner RR, Falutz J, Testa MA, et al. The impact of tesamorelin (TH9507), a growth hormone releasing factor analogue, on body image and health-related quality of life in HIV-infected patients with abdominal fat accumulation. Antivir Ther 2007; 12:L33.
80. Fontdevila J, Berenguer J, Prades E, et al. Autologous fat grafts are safe and durable in HIV-infected adults with facial lipoatrophy. Antivir Ther 2007; 12:L34.
81. Orlando G, Guaraldi G, Squillace N, et al. Effectiveness and long-term durability of autologous fat transplants for HIV-related face lipoatrophy. Antivir Ther 2007; 12:L35.
82. Rector RS, Warner SO, Liu Y, et al. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol Endocrinol Metab 2007; 293:E500-E506.
83. Perez-Martin A, Raynaud E, Mercier J. Insulin resistance and associated metabolic abnormalities in muscle: effects of exercise. Obes Rev 2001; 2:47-59.
84. Kadoglou NP, Iliadis F, Liapis CD, et al. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2007; in press.
85. Roberts CK, Ng C, Hama S, et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 2006; 101:1727-1732.
86. Duncan GE. Exercise, fitness, and cardiovascular disease risk in type 2 diabetes and the metabolic syndrome. Curr Diab Rep 2006; 6:29-35.
87. Panunti B, Fonseca V. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascul Pharmacol 2006; 45:29-35.
88. Takano H, Hasegawa H, Zou Y, et al. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des 2004; 10:2779-2786.
89. Reeds DN, Cade WT, Mondy K, et al. Pioglitazone with or without exercise training reduces liver lipid content and improves insulin sensitivity in HIV with impaired glucose tolerance (IGT). Antivir Ther 2007; 12:L14.